Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is playing an increasingly important role in indications such as gastric and gastroesophageal junction (GEJ) adenocarcinoma. Although biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions and cost-containment strategies.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n \u00b7 What factors largely influence payers\u2019 reimbursement decisions for biomarker-driven therapies in NSCLC, bladder cancer, and gastric and GEJ adenocarcinoma? What restrictions do they impose?<\/p>\n \u00b7 Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?<\/p>\n \u00b7 What impact do reimbursement and cost have in oncologists\u2019 decisions to prescribe biomarker-driven therapies?<\/p>\n \u00b7 What are payer opinions of emerging agents, and how will oncologists\u2019 prescribing patterns change with the launch of new therapies?<\/p>\n \u00b7 What factors influence reimbursement and access of companion biomarker tests?<\/p>\n GEOGRAPHY:<\/strong> United States.<\/p>\n PRIMARY RESEARCH:<\/strong> Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs\/MDs).<\/p>\n KEY DRUGS COVERED:<\/strong><\/p>\n Tagrisso, Tarceva, Gilotrif, Iressa, Vizimpro, Rybrevant, Lumakras, Tabrecta, Tepmetko, Retevmo, Gavreto, Keytruda, Tecentriq, Balversa, Opdivo, and Enhertu<\/p>\n CONTENT HIGHLIGHTS:<\/strong><\/p>\n\n